This symposium covered a wide range of topics of interest to both general physicians and specialists in haematology. Problems commonly encountered by acute physicians were explored, including the management of over-anticoagulation, thrombocytopenia associated with thrombosis and dealing with current and emerging risks of blood transfusion. Updates on the management of chronic lymphocytic leukaemia, multiple myeloma and Hodgkin’s lymphoma were presented. The discovery of the JAK2V617F mutation and the use of tyrosine kinase inhibitors in chronic myeloid leukaemia have changed the way we diagnose and treat myeloproliferative disorders. New approaches to monitoring and treating transfusional iron overload were discussed. In the field of stem cell transplantation, the vogue for reduced intensity allogeneic transplants has allowed older patients to benefit from this treatment approach.
Get full access to this article
View all access options for this article.
References
1.
HamblinTJDavisZGardinerAUnmutated IgVH genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood1999; 94:1848–54.
2.
DamleRNWasilTFaisFIg V gene mutations and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood1999; 94:1840–7.
3.
DöhnerHStilgenbauerSBennerAGenomic aberrations and survivial in chronic lymphocytic leukemia. N Engl J Med2000; 343:1910–6.
4.
StilgenbauerSDöhnerH. Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy. N Engl J Med 2002; 347: 452–3.
5.
CatovskyDRichardsSMatutesE Fludarabine plus cyclophosphamide improves response and progression-free survival in chronic lymphocytic leukaemia. Lancet 2007; 370: 230–9.
6.
MoretonPKennedyBLucasGEradication of minimal residual disease (MRD) in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol2005; 23:2971–9.
7.
SmithAWisloffFMyeloma ForumSamson D on behalf of the UKNordic Myeloma Study Group and the British Committee for Standards inHaematology. Guidelines on the diagnosis and management of multiple myeloma. Br J Haematol 2005; 132: 410–51.
8.
WooSBHellsteinJWKlamerJR.Systematic review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006; 144:753–61. Erratum in: Ann Intern Med 2006; 145(3):235.
9.
MarxRESawatariYFortinMBisphosphonates – induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention and treatment. J Oral Maxillofac Surgery2005; 63:1567–75.
10.
BadrosAWeikelDSalamaAOsteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol2006; 24:945–52.
11.
BamiasAKastritisEBamiaCOsteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol2005; 23:8580–7.
12.
MiglioratiCASchubertMMPetersonDE Bisphosphonateassociated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy. Cancer 2005; 104: 83–93.
13.
DimopoulosMAKastritisEAnagnostopoulosAOsteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid. Haematologica2007; 91:968–71.
14.
ZervasKVerrouETeleioudisZIncidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients. Br J Haematol2006; 134:620–30.
15.
EngertAFranklinJEichHTTwo cycles of doxorubicin, bleomycin, vinblastine and dacarbazine plus extended field radiotherapy is superior to radiotherapy alone in favourable Hodgkin’s lymphoma: final results of the GHSG HD7 trial. J Clin Oncol2007; 25:3495–502.
16.
National Cancer Research Network PET trial in Hodgkin’s Disease. Trial protocol available from: http://public.ukcrn.org.uk/Search/Portfolio.aspx?Level1=1&Level2=9&Level3=23&Status=34
17.
DiehlVFranklinJPfreundschuhMStandard risk and increased dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin’s disease. N Engl J Med2003; 348:2386–95.
18.
DrukerBJGuilhotFO’BrienSGFive-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med2006; 355:2408–17.
19.
BaccaraniMSaglioGGoldmanJEvolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European Leukemia Net. Blood2006; 108:1809–20.
20.
McMullinMFReillyJTCampbellPAmendment to the guidelines for the diagnosis, investigation and management of polycythaemia/erythrocytosis. Br J Haematol2007; 138:812–23.
21.
BeyethRJQuinnLMLandefieldCS.Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med1998; 105:91–9.
22.
PalaretiGLealiNCoccheriSBleeding complications of oral anticoagulant therapy: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet1996; 348:423–8.
23.
KeelingDDavidsonSWatsonH.The management of heparininduced thrombocytopenia. Br J Haematol2006; 133:259–69.
24.
DavisAB, O’SulliVan C, Jarritt PH. Value of sequential monitoring of left ventricular ejection fraction in the management of thalassaemia major. Blood2004; 104:263–9.
25.
AndersonLJHoldenSDavisBCardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J2001; 22:2171–9.
26.
CalandraGMcCartyJMcGuirkJAMD3100 plus G-CSF can successfully mobilize CD34 + cells from non-Hodgkin’s lymphoma, Hodgkin’s disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data. Bone Marrow Transplant2008; 41:331–8.
27.
FlomenbergNDevineSMDipersioJFThe use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood2005; 106:1867–74.
